Subsequent Compound definition

Subsequent Compound means, as to a Taisho Activated Receptor, a subsequent CART Identified Compound developed by Taisho and/or Taisho's Licensee(s) subsequently to the preceding CART Identified Compound precedently developed for the same or similar therapeutic indication as the preceding CART Identified Compound, that is developed after the receipt of Marketing Authorization for the preceding CART Identified Compound or that is simultaneously developed with the preceding CART Identified Compound with the intent to commercialize both Compounds. For the purpose of determination of such intent, a subsequent CART Identified Compound shall be deemed Subsequent Compound if Phase 3 Clinical Study thereof is started prior to the launch of the preceding CART Identified Compound.
Sample 1Sample 2
Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented or otherwise the subject of [*] conducted, by or on behalf of Genentech or its Affiliate or Sublicensee, but excluding [*], whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period; (b) that is [*] from a Third Party during the Restriction Period; or (c) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described in (a), (b) or (c) above.
Sample 1Sample 2
Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented after the end of the Next Gen Research Term but during the Restriction Period by or on behalf of GNE or a Sublicensee, whether solely or jointly; (b) that is the [*] by or on behalf of GNE or a Sublicensee, whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period, but excluding any such Compound that is a [*] at the time of such [*]; (c) to which [*] such Compound, or an [*] from a Third Party, whether directly or indirectly, during the Restriction Period; or (d) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or [*] of a Compound described in (a), (b), or (c) above. For clarity, Subsequent Compounds do not include Compounds that are (x) [*], or invented by or on behalf of, or that are the subject of [*] by or on behalf of, either (i) [*] (including through [*] that are not [*]) or (ii) [*] in the course of its activities conducted on [*] or otherwise [*] or (y) Roche Acquired Compounds as long as, in each case of (x) and (y), such Compound (1) does not [*], (2) and [*] are and were not [*] during the Restriction Period, (3) is not [*] above, and (4) was invented, [*], as applicable, without [*].
Sample 1Sample 2

Examples of Subsequent Compound in a sentence

  • Arena acknowledges and agrees that Taisho shall have sole discretion to: (i) determine which CART Identified Compound to develop as a first Drug Product, Back-Up Compound or Subsequent Compound; and (ii) whether or not to continue development of any CART Identified Compound or Drug Product.

  • For a Subsequent Compound, the payment shall be made only at the first occurrence, if any, of a milestone set forth below as to the Drug Product first applicable to such milestone that incorporate the Subsequent Compound, regardless of formulation and/or indication of the Drug Product.

  • Taisho shall provide Notice to Arena of its decision to implement Taisho Development of a Subsequent Compound.

  • Arena acknowledges and agrees that in the event that Taisho discontinues development of a Subsequent Compound prior to the Market Authorization of the preceding CART Identified Compound, then any milestone payments otherwise due by Taisho for such Subsequent Compound under this Agreement shall not be required to be made by Taisho.

  • The term “product data” means manufacturer’s catalog sheets, brochures, standard diagrams, illustrations, schedules, performance charts, test data, standard schematic drawings, specifications and installation instructions.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in Japan, Taisho shall provide Arena with an approval fee of [**********************************] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • Upon the filing of an IND in the Territory for a Subsequent Compound, Taisho shall provide to Arena a Reduced IND Milestone of [*************************** (*******)] within thirty (30) days of such filing.

  • Upon the filing of an IND in the Territory for a Subsequent Compound, Taisho shall provide to Arena a Reduced IND Milestone of [******************************************] within thirty (30) days of such filing.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in the United States, Taisho shall provide Arena with an approval fee of [**********************************] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • IN WITNESS WHEREOF, Consultant and District execute this Agreement.


More Definitions of Subsequent Compound

Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented or otherwise the subject of [*] conducted, by or on behalf of Genentech or its Affiliate or Sublicensee, but excluding [*], whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period; (b) that is [*] from a Third Party during the Restriction Period; or (c) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described in (a), (b) or (c) above. [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential Execution Version
Sample 1
Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented or otherwise the subject of [*] conducted, by or on behalf of Genentech or its Affiliate or Sublicensee, but excluding [*], whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period; (b) that is [*] from a Third Party during the Restriction Period; or (c) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described in (a), (b) or (c) above. [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential Execution Version
Sample 1

Related to Subsequent Compound

  • Exempt compound means the same as defined in Rule 2.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Combination Product means (a) a product containing a Licensed Product together with one or more other active ingredients that have independent biologic or chemical activity when present alone that are sold as a single unit, or (b) a Licensed Product together with one or more products, devices, pieces of equipment or components thereof, that are sold as a single package at a single price.

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).

  • X-ray field means that area of the intersection of the useful beam and any one of the set of planes parallel to and including the plane of the image receptor, whose perimeter is the locus of points at which the exposure rate is one-fourth of the maximum in the intersection.

  • Additional Product means any Product identified as such in the Product Terms and chosen by Enrolled Affiliate under this Enrollment.

  • Compounds means a small molecule HMT inhibitor.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Combination Products means any product containing both a pharmaceutically active agent or ingredient which constitutes a Licensed Product and one or more other pharmaceutically active agents or ingredients which do not constitute Licensed Products.

  • Program Patent Rights means all Patent Rights that claim or cover patentable Program Know-How, including any Program-Specific Patent Rights.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Licensed Product means any method, process, composition, product, service, or component part thereof that would, but for the granting of the rights set forth in this Agreement, infringe a Valid Claim contained in the Licensed Patents.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Additional Indication means any indication other than the Initial Indication.